|
Apex Lab gets approval for repurposing herbal formulation, Clevira, as adjuvant therapy for Covid-19
|
|
Peethaambaran Kunnathoor, Chennai
June 07 , 2021
|
|
|
The Chennai-based pharma company Apex Laboratories has received Government of India’s approval for repurposing its poly-herbal antiviral formulation, Clevira tablets, as an adjuvant therapy for mild to moderate conditions of Covid-19, sources from the company informed Pharmabiz.
The company launched the product in the Indian market way back in 2017 following the outbreak of the dengue fever and it proved effective for curing all viral infections. Apex will soon market the herbal formulation as an adjuvant therapy for patients with mild and moderate symptoms of Covid-19 in India.
According to information from Apex Lab, Clevira is an antiviral formulation for the treatment of various viral infections including fever associated with or without thrombocytopenia. In addition to an antiviral agent, the efficacy of the drug has been proven as analgesic, antipyretic and reversal of thrombocytopenia. The medicine has taken for extensive study by researches and scientists in animal models for its safety aspects and in human subjects in the phase II and III clinical trials.
M Radhakrishnan, vice-president, corporate affairs at Apex said, for repurposing Clevira for Covid-19 cases, a phase III clinical trial was carried out at the government multi-super-specialty hospital at Omandurar government estate in Chennai with the approval of the state government. The trial outcomes revealed that Clevira proved 86% recovery rate on the 5th day of treatment in patients with mild to moderate symptoms of Covid-19. However, on the 10th day it showed hundred percent recoveries. It has been proven that the drug has no side-effects on kidney and liver functions. He said during the study period of Clevira treatment no disease progression has been noticed.
He said the study reports were submitted to the government of Tamil Nadu, Indian Council of Medical Research and to the Ministry of Ayush in last July.
“In April this year the Ministry of Ayush granted the approval to Clevira as a supporting therapy to mild and moderate Covid symptoms after various stages of scrutiny and deliberations by various technical review committees. The approval is the first-of its-kind in the country and it has been granted after a long process of scrutiny by the scientists at the Central Council for Research in Ayurvedic Sciences (CCRAS) and by the Inter Disciplinary Technical Review Committee (ITRC) headed by Dr.SK Maulik, former professor at the Department of Pharmacology in the All India Institute of Medical Sciences in New Delhi,” says Radhakrishnan.
According to Dr. Subhashini Vanangamudi, executive director of Apex Lab, the company is thankful to government of India for having approved the efficacy of Clevira for treating Covid-19 patients as an adjunct therapy. “We are eager to prove the strength and efficacy of Indian medicine in future for other conditions also. We strongly believe that the Indian medicines will reach great heights and hope that a new era will be started with scientifically proven herbal formulations,” she said.
The dosage of the drug is one tablet each twice a day after food and the regimen should continue for two weeks.
|
|
|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|